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Peptide motifs are often used for protein-protein in-
teractions. We have recently demonstrated that an-
kyrin repeats of ANKRA2 and the paralogous bare
lymphocyte syndrome transcription factor RFXANK
recognize PxLPxL/I motifs shared by megalin, three
histone deacetylases, and RFX5. We show here
that that CCDC8 is a major partner of ANKRA2 but
not RFXANK in cells. The CCDC8 gene is mutated
in 3M syndrome, a short-stature disorder with addi-
tional facial and skeletal abnormalities. Two other
genes mutated in this syndrome encode CUL7 and
OBSL1. While CUL7 is a ubiquitin ligase and OBSL1
associates with the cytoskeleton, little is known
about CCDC8. Binding and structural analyses reveal
that the ankyrin repeats of ANKRA2 recognize a
PxLPxL motif at the C-terminal region of CCDC8.
The N-terminal part interacts with OBSL1 to form a
CUL7 ligase complex. These results link ANKRA2
unexpectedly to 3M syndrome and suggest novel
regulatory mechanisms for histone deacetylases
and RFX7.
INTRODUCTION
Primordial dwarfism comprises heterogeneous diseases that
involve diverse molecular and cellular mechanisms (Klingseisen
and Jackson, 2011). 3M syndrome is a primordial growth disor-
der named after three principal scientists (Miller, McKusick, and
Malvaux) who first reported this genetic disease four decades
ago (Miller et al., 1975). Such patients display prenatal and post-
natal growth retardation along with frontal bossing, triangular
face, midface hypoplasia, and other distinct facial abnormalities700 Structure 23, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rightsbut possess typically normal intelligence, indicating that facial
but not brain development is affected (Clayton et al., 2012; Han-
son et al., 2011, 2012; Litterman et al., 2011). Growth hormone is
often normal in the patients and their response to recombinant
growth hormone therapy is variable but typically poor, so the
hormone itself may not be the culprit (Clayton et al., 2012). A
causal gene was first mapped to chromosome 6p21.1 and found
to encode CUL7 (cullin 7) (Huber et al., 2005). A known E3 ubiq-
uitin ligase (Arai et al., 2003; Dias et al., 2002; Furukawa et al.,
2003), CUL7 stimulates ubiquitination of p53 (Andrews et al.,
2006), insulin receptor substrate (Litterman et al., 2011; Xu
et al., 2008), TBC1D3 (TBC1 domain family member 3) (Kong
et al., 2012), and hematopoietic progenitor kinase 1 (Wang
et al., 2014). Mutations were also found in an unrelated gene en-
coding OBSL1 (obscurin-like 1), a large protein similar to the
N-terminal portion of the giant 720-kDa sarcomeric signaling
regulator obscurin (Geisler et al., 2007; Hanson et al., 2009).
Two recent studies have discovered mutations on a third gene,
CCDC8 (coiled-coil domain containing 8) (Al-Dosari et al.,
2012; Hanson et al., 2011). This gene was so named because
its encoded protein contains a putative coiled-coil domain ac-
cording to bioinformatic analysis (GenBank accession no.
Q9H0W5). Due to the mutations in patients with 3M, CUL7,
OBSL1, and CCDC8 are considered to function in the same mo-
lecular and cellular pathways to regulate protein ubiquitination
and control organismal growth (Hanson et al., 2012; Litterman
et al., 2011). However, further studies are needed to substantiate
this hypothesis and to elucidate the underlying mechanisms.
Ankyrin-repeat family A protein 2 (ANKRA2) contains five an-
kyrin repeats and was initially identified as a binding partner of
megalin, also known as low-density lipoprotein receptor-related
protein 2 (LRP2) (Rader et al., 2000). This multiligand receptor is
located in the plasma membrane of absorptive epithelial cells to
regulate protein uptake from the luminal space (Christensen and
Birn, 2002). During yeast two-hybrid screening, ANKRA2 was
identified as a binding partner of histone deacetylase 4
(HDAC4) and HDAC5 (McKinsey et al., 2006; Wang et al.,reserved
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Figure 1. Proteomic Identification of
ANKRA2-Interacting Proteins
(A) Schematic representation of human ANKRA2
and RFXANK along with the fly homolog (CG5846,
NP_609333). Ankyrin-repeat domains are de-
picted in green, with sequence similarity and
identity toward human ANKRA2 indicated as a
percentage. The arrow denotes that ankyrin-
repeat domains of human ANKRA2 and RFXANK
specifically recognize PxLPxL/I motifs. The
C. elegans genome does not encode a homolo-
gous protein.
(B) List of proteins associated with stably ex-
pressed ANKRA2. GFP-ANKRA2 and GFP were
stably expressed in HEK293 cells for affinity puri-
fication and mass spectrometry. The three pro-
teins linked to 3M syndrome and the F-box protein
FBXW8 are highlighted in yellow, while the green
number sign (#) labels three proteins associated
with BLS. The red asterisk (*) denotes proteins
possessing PxLPxL/I motifs.
(C) Cartoons showing how RFXANK and ANKRA2
target RFX7 and two complexes linked to BLS and
3M syndrome. The preference of RFX7 for
ANKRA2 is based on binding affinity (see below).
See also Figures S1–S3 and Tables S1 and S2.2005). These two paralogous deacetylases function as transcrip-
tional corepressors to regulate gene expression in the nucleus
(Yang and Seto, 2008). Furthermore, the cytoplasmic tail of meg-
alin shares a conserved PxLPxL/I motif with the N-terminal reg-
ulatory regions of HDAC4, HDAC5, and perhaps also HDAC9 for
specific interaction with ankyrin repeats of ANKRA2 (Xu et al.,
2012).
The ankyrin repeats are highly homologous to those of
RFXANK (regulator factor X 5 [RFX5]-interacting ankyrin-repeat
protein) (Lin et al., 1999; Masternak et al., 1998; Nagarajan
et al., 1999; Rader et al., 2000; Xu et al., 2012). Mutations on
the RFXANK gene are well known to cause the immune disorder
bare lymphocyte syndrome (BLS) (Masternak et al., 1998; Na-Structure 23, 700–712, April 7, 2015garajan et al., 1999; Reith and Mach,
2001). RFXANK forms a trimeric tran-
scription factor complex with RFX5
and RFXAP (RFX5-associated protein),
encoded by two other genes that are
mutated in patients with BLS (Reith and
Mach, 2001; Ting and Trowsdale, 2002).
This trimeric complex recognizes an
enhancer X-box sequence motif, shared
by major histocompatibility class II
(MHC-II) genes, to recruit the MHC-II
transcriptional coactivator CIITA (en-
coded by the fourth gene mutated in
patients with BLS) for activation of gene
expression (Reith and Mach, 2001; Ting
and Trowsdale, 2002). Similar to the
ANKRA2 interaction with megalin and
the deacetylases, RFXANK recognizes a
PxLPxL motif of RFX5 via its ankyrin-
repeat domain (Xu et al., 2012). There-fore, ANKRA2 and RFXANK recognize PxLPxL/I motifs on
diverse partners. Despite their sequence and structure similarity,
these two ankyrin-repeat proteins display specificity for their
partners (Xu et al., 2012). ANKRA2 is more specific for megalin
and the deacetylases, whereas RFXANK prefers RFX5 (Xu
et al., 2012). Sequences within the PxLPxL/I motifs and the flank-
ing residues dictate this specificity. For example, in RFX5, the
methionine preceding the motif and the proline at the +2 position
contribute greatly to RFXANK association (Xu et al., 2012). A
highly similar ankyrin-repeat domain is present in Drosophila
but not Caenorhabditis elegans (Figure 1A; Figure S1), suggest-
ing that the binding mode is evolutionarily conserved from the fly
to humans.ª2015 Elsevier Ltd All rights reserved 701
An interesting question is whether there are additional pro-
teins adopting such a mode for interacting with ANKRA2 and
RFXANK. Here, we demonstrate that the 3M syndrome protein
CCDC8 interacts specifically with ANKRA2 but not with
RFXANK. Protein binding and crystal structure analyses
confirmed that ANKRA2 recognizes CCDC8 through a PxLPxL
motif located at the C-terminal domain. Different from
ANKRA2, OBSL1 interacts with the conserved N-terminal
domain of CCDC8 to bridge the association with CUL7. In
addition, this ligase and ANKRA2 bind to HDAC4 in an antag-
onistic fashion. These results unravel a previously unappreci-
ated link of ANKRA2 to 3M syndrome and yield new insights
into mechanisms whereby HDAC4 and related deacetylases
are regulated.
RESULTS
Two Groups of Disease-Causing Partners of ANKRA2
and RFXANK
PxLPxL/I motifs are short sequences present in many proteins.
With proper flanking residues, such motifs are sufficient for spe-
cific recognition by ANKRA2 and RFXANK (Xu et al., 2012), so an
interesting question is whether any new proteins utilize similar
motifs for interaction with ANKRA2 or RFXANK. To investigate
this, we performed systematic mass spectrometry to identify
proteins copurified with ANKRA2 and RFXANK. For this, GFP
fusion proteins were expressed for affinity purification on GFP-
Trap beads due to their high recovery efficiency (Rothbauer
et al., 2008). As listed in Tables S1 and S2, when transiently ex-
pressed, GFP-ANKRA2 and -RFXANK coimmunoprecipitated
over ten endogenous proteins from HEK293 cell extracts. The
proteins were not detected with similar purification with GFP-
CRTC2 (CREB-regulated transcription coactivator 2, Tables S1
and S2), indicating that the coimmunoprecipitation (co-IP) is
specific. This notion received further support from identification
of known partners. Both ANKRA2 and RFXANK coprecipitated
RFX5 and RFXAP (Table S1). Notably, RFX5 was recovered as
the top partner for RFXANK (Table S2) and one of the top ones
for ANKRA2 (Table S1). RFXANK forms a trimeric transcription
factor complex with RFX5 and RFXAP (Reith and Mach, 2001;
Ting and Trowsdale, 2002) and ANKRA2 may play a similar
role (Krawczyk et al., 2005; Long and Boss, 2005). In addition,
ANKRA2 coprecipitated HDAC5 (Table S1), which is consistent
with the published reports that ANKRA2 interacts with this de-
acetylase (McKinsey et al., 2006; Wang et al., 2005; Xu et al.,
2012). HDAC4 was not identified (Table S1), perhaps due to its
low level in the cells used or its regulated interaction with
ANKRA2 (Wang et al., 2005; Xu et al., 2012). Among other estab-
lished partners of ANKRA2, megalin is a membrane-associated
receptor whose expression is restricted to the absorptive epithe-
lial cells (Christensen and Birn, 2002; Rader et al., 2000) andmay
not be present in HEK293 cells. Interestingly, in addition to com-
mon binding partners, ANKRA2 and RFXANK coprecipitated
distinct proteins (Tables S1 and S2), which is consistent with
their distinct preference for partners (Xu et al., 2012). Tominimize
potential artifacts resulting from transient expression, we stably
expressed GFP-ANKRA2 for affinity purification. This strategy
recovered a set of proteins (Figure 1B; Figure S2) similar to those
from transient expression and affinity purification (Table S1),702 Structure 23, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rightsfurther supporting the specificity of affinity purification in both
strategies.
While RFX5 was identified as the top partner of RFXANK
(Table S2), the 3M syndrome protein CCDC8 was recovered
unexpectedly as the major partner of ANKRA2 (Figures 1B
and 1C; Table S1). CCDC8 did not coprecipitate with RFXANK
(Table S2). CCDC8 is a novel protein linked to 3M syndrome
(Al-Dosari et al., 2012; Hanson et al., 2011). The other two pro-
teins affected in the syndrome are CUL7 and OBSL1 (Hanson
et al., 2009; Huber et al., 2005). Both copurified with ANKRA2
but not with RFXANK (Figure 1B; Tables S1 and S2). Moreover,
FBXW8, an F-box protein interacting with CUL7 and regulating
its ligase activity (Arai et al., 2003; Dias et al., 2002; Litterman
et al., 2011; Xu et al., 2008), copurified with GFP-ANKRA2
(Figure 1B). These results suggest that ANKRA2 forms a com-
plex with CCDC8, OBSL1, CUL7, and FBXW8, four proteins
with known roles in 3M syndrome, providing the molecular
basis underlying the genetic links to this disease (Figure 1C,
right).
Related to RFX5, RFX7 was identified as the second top part-
ner for both ANKRA2 and RFXANK (Figure 1C; Table S1). RFX7
is a poorly characterized protein with a role in breast cancer and
may regulate brain development (Aftab et al., 2008; Bae et al.,
2014; Yau et al., 2010). Sequence analysis revealed that RFX7
shows high similarity to RFX5 within the N-terminal RFX do-
mains used for DNA binding (Figures S3A–S3C) (Aftab et al.,
2008). Importantly, within the RFX domain, there is a PxLPxL
motif (Figures S3A–S3C). This motif is conserved in the
Drosophila homolog of RFX5 and RFX7 (Figures S3A–S3C).
The MPxLPxL motif of RFX5 mediates association with RFXANK
(Xu et al., 2012), although this may not be the sole surface
for RFXANK association (Krawczyk et al., 2005). Interaction of
RFX7 with RFXANK or ANKRA2 has not been reported, but
the high similarity to RFX5 suggests that RFX7 may utilize its
PxLPxL motif to bind ANKRA2 and RFXANK (Figure S3). Thus,
along with published reports (Krawczyk et al., 2005; Long and
Boss, 2005; Reith and Mach, 2001; Ting and Trowsdale,
2002), these results confirm that RFXANK and ANKRA2 act
through RFX5, and perhaps also RFX7, to regulate gene expres-
sion (Figure 1C).
In addition to the above two groups of disease-associated
proteins (Figure 1C), the E3 ubiquin ligase HUWE1 and the poorly
characterized protein C20orf117 (recently named SOGA1 [sup-
pressor of glucose_autophagy associated 1]) copurified with
ANKRA2 and RFXANK (Figure 1C; Table S1). Notably, HUWE1
and C20orf117 were also among the top-ranked hits, suggesting
their potential functional relevance.
As reported about HDAC4/5/7, RFX5, megalin (Xu et al., 2012),
and noted above for RFX7 (Figure S3), an interesting possibility is
whether any of the newly identified proteins possess the PxLPxL/
I motif. To examine this, we inspected amino acid sequences of
the identified candidates. Among all of the proteins newly identi-
fied in the mass spectrometric analyses (Figure 1B; Tables S1
andS2), CCDC8 is the only other protein possessing a conserved
PxLPxL/I motif (Figure 2A). As described above, CCDC8 was
identified as the major partner of ANKRA2 (Figure 1B; Table
S1). Because of these two unique features (Figure 2A) and its
link to 3M syndrome (Figure 1C) (Al-Dosari et al., 2012; Hanson
et al., 2011), we characterized CCDC8 further.reserved
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Figure 2. CCDC8Possesses a PxLPxLMotif
for ANKRA2 Interaction
(A) CCDC8 contains highly conserved domains at
both ends, with a portion of the N-terminal domain
similar to the paraneoplastic Ma antigen (PNMA)
family of proteins. This portion, named the CP
(CCDC8 and PNMA homologous) domain, harbors
a BH3-like motif (Chen and D’Mello, 2010). The
region C-terminal to the CP domain is conserved
and possesses a putativeWWdomain. Themiddle
QR domain contains nine AAxxQR repeats, absent
in lower mammals such as mice and rats (Fig-
ure S4). Embedded within the C-terminal coiled
coil is a PxLPxL/R motif, conserved from guinea
pig to humans. Positions of thee 3M syndrome-
causing mutations are also indicated (Al-Dosari
et al., 2012; Hanson et al., 2011).
(B) Co-IP showing that CCDC8 interacts with
ANKRA2, but not with its point mutant W188A or
with RFXANK. GFP-X, GFP fusion protein of an
unrelated protein. Expression vectors for the
indicated GFP fusion proteins were separately
transfected into HEK293 cells along with the
plasmid for Flag-CCDC8 (lanes 1–4, 7, 8–11, and
14) or the corresponding empty vector (lanes 5–6
and 12–13) for affinity purification and immuno-
blotting.
(C) Co-IP demonstrating that ANKRA2 interacts
with CCDC8 but not its C-terminal truncation
mutant (CCDC8N) or the point mutants P503A and
T504A. See also Figures S4 and S5.The PxLPxL Motif of CCDC8 Mediates Interaction with
ANKRA2
The PxLPxL motif is embedded within the C-terminal domain of
CCDC8 and is conserved from mice to humans (Figure 2A; Fig-
ure S4). Notably, CCDC8 is specific to mammals and an evolu-
tionarily recent protein, as its orthologs are absent in model
organisms such as Drosophila, zebrafish, or Xenopus. Strikingly,
human CCDC8 possesses a QR domain (containing multiple
AAxxQR repeats) highly divergent in mouse and rat Ccdc8 (Fig-
ure S4). Like the C-terminal domain, the N-terminal domain isStructure 23, 700–712, April 7, 2015highly conserved (Figure 2A; Figure S4).
The N-terminal half of the N-terminal
domain displays similarity to the N-termi-
nal parts of PNMA (paraneoplastic Ma
antigen) proteins, but the functional signif-
icance remains elusive. The PNMA family
is linked to the paraneoplastic neurolog-
ical syndrome (Schuller et al., 2005), but
the molecular function remains poorly
characterized. Some evidence suggests
a role in inducing neuronal death through
a BH3-like motif (Figure 2A; Figures S5A
and S5B) (Chen and D’Mello, 2010).
To analyze interaction between
CCDC8 and ANKRA2, we expressed
them for co-IP. As shown in Figure 2B,
CCDC8 specifically coprecipitated with
ANKRA2, supporting their interaction
(lanes 2 and 9). This interaction was spe-cific as no such co-IPwas detectedwith RFXANK (lanes 1 and 8).
We also analyzed two point mutants of ANKRA2. Mutant K31R
affects a putative sumoylation site located outside the ankyrin-
repeat domain, whereas mutant W188A impairs interaction
with HDAC4 and megalin (Xu et al., 2012). As shown in Figure 2B
(lanes 3–4 and 10–11), mutant K31R but not W188A coprecipi-
tated with CCDC8, indicating that CCDC8 adopts a similar
mode of interaction with ANKRA2 as HDAC4 and megalin.
We next mapped the ANKRA2 binding site on CCDC8. For
this, we analyzed a CCDC8 mutant lacking the C-terminalª2015 Elsevier Ltd All rights reserved 703
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Figure 3. ITC Analysis of the Interaction of
CCDC8 Peptides with ANKRA2, RFXANK,
and 14-3-3
(A) Amino acid sequence of the unmodified
CCDC8 peptide used for ITC analysis. The PxLPxL
motif is highlighted in bold and aligned with the
consensus sequence for ANKRA2/RFXANK bind-
ing, with an RxxTxP motif indicated in italics.
(B and C) ITC measurement of affinities for the
ankyrin repeats of ANKRA2 and RFXANK binding
toward the unmodified CCDC8 peptide shown
in (A).
(D) Amino acid sequence of the phosphorylated
CCDC8 peptide used for ITC analysis. The PxLPxL
motif is highlighted in bold, and the embedded
potential 14-3-3 binding site is alignedwith a 14-3-
3 binding consensus sequence (in italics).
(E and F) ITC measurement of affinities for the
ANKRA2 ankyrin repeats and 14-3-3g binding to
the phosphorylated peptide shown in (D).coiled-coil domain. As shown in Figure 2C (lanes 1–5 and 7–12),
this mutant exhibited much weaker ANKRA2 binding compared
with full-length CCDC8, indicating that a major binding site is
located at the C-terminal domain. In similar assays, we could
not assess whether the C-terminal domain is sufficient for the
interaction, as it could not be expressed in the cells (data not
shown). To determine whether the PxLPxL motif is necessary
for CCDC8 to bind ANKRA2, we engineered two point mutants,
P503A and T504A in the 500-PRLPTL-505 sequence. Compared
with wild-type CCDC8, P503A displayed much weaker co-IP
with ANKRA2 (lanes 6 and 13), confirming the importance of
P503 in ANKRA2 association. The T504A mutation also abol-
ished the interaction (lanes 7 and 14), although the reason
remains unclear. Together, the results from these co-IP experi-704 Structure 23, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rights reservedments demonstrate that in cells, CCDC8
uses its PxLPxL motif for ANKARA2
interaction.
To determine whether the motif is suffi-
cient for interactionwithANKRA2,weper-
formed isothermal titration calorimetry
(ITC) with a peptide corresponding to res-
idues 494–510 of CCDC8 (Figure 3A). As
shown in Figure 3B, the peptide bound
efficiently to the ankyrin-repeat domain
of ANKRA2 with a Kd value of 0.18 mM.
By contrast, the binding to the corre-
sponding domain of RFXANK was weak
(Kd >500 mM, Figure 3C). As phosphoryla-
tion of S350 within the PxLPxL motif of
HDAC4 impairs ANKRA2 association (Xu
et al., 2012), we wondered whether this
is also the case with CCDC8. The corre-
sponding residue in CCDC8 is R501, but
T504 is just a few residues away. We
thus analyzed the same peptide with
T504 replaced with phospho-threonine
(Figure 3D). In comparison with the regu-
lar peptide, this phosphopeptide ex-hibited a slightly lower affinity for ANKRA2 (Kd = 0.43 mM versus
0.18 mM, cf. Figures 3E and 3B), indicating that phosphorylation
has minimal effects on the binding. T504 constitutes a potential
14-3-3 binding site (Figure 3D) and 14-3-3 may compete with
ANKRA2 in binding to the same region. But 14-3-3 exhibitedmin-
imal binding to the phosphopeptide (Kd >300 mM, Figure 3F).
The preference of CCDC8 for ANKRA2 over RFXANK is remi-
niscent of that of HDAC4 andmegalin (Figure 4A) (Xu et al., 2012).
Notably, the affinity for ANKRA2 was even higher than that of
HDAC4, megalin, or RFX7 (Figure 4A; Figure S6), which may
explain why it was recovered as the top partner (Figure 1C;
Tables S1 and S2). Sequence comparison revealed that the
amino acid sequence of the CCDC8motif ismore similar to those
of HDAC4, megalin, and RFX7 than to that of RFX5 (Figure 4B),
AB
Figure 4. Binding Affinity and Sequence Comparison of Various
Known PxLPxL/I Motifs
(A) Summary of the binding affinity of different PxLPxL/I motifs for ANKRA2,
RFXANK, and 14-3-3. Kd values for HDAC4, megalin, and RFX5 are derived
from a previous report (Xu et al., 2012), whereas the values for CCDC8 and
RFX7 are based on ITC analyses performed in this study. ND, not determined.
(B) Sequence alignment of known and putative PxLPxL/I motifs. Key residues
of the PxLPxL/I motifs are highlighted in red, with the phosphorylatable resi-
dues in green and P175 of RFX5 in blue. This residue is key to making RFX5
preferable for RFXANK binding (Xu et al., 2012); because of this proline, the
binding pocket of RFXANK receives M173 (also in blue) instead of P174 of
RFX5. Although M173 is conserved in RFX7, P175 of RFX5 is replaced with
threonine in RFX7. Thus, the core motif of RFX7 is more similar to those of
HDAC4 and megalin than to that of RFX5.
Table 1. Parameter Statistics for the Complex Crystal Structure
of the Ankyrin-Repeat Domain of ANKRA2 Bound to the CCDC8
Peptide
Space group P21
Cell a, b, c (A˚), b () 38.73, 49.79, 41.24, 98.23
Resolution range (high-resolution
shell)a (A˚)
30.00–1.80 (1.90–1.80)
Number of unique reflections (Friedel)a 14,082 (1,988)
Completenessa (%) 98.5 (94.8)
Rsym
a 0.047 (0.650)
Meana ((I)/s(I)) 16.2 (2.1)
Redundancya 3.7 (3.7)
Refinement resolution (A˚) 26.15–1.80
Reflections work/free 13368/712
Rwork/Rfree 0.196/0.209
Number of atoms/average B factor (A˚2)
ANKRA2 protein 1246/30.1
CCDC8 peptide 87/37.7
Rmsd bonds (A˚)/angles () 0.014/1.4
Ramachandran plot favored/outliers (%) 99.4/0.0
Rmsd, root-mean-square deviation.
aValues in parentheses correspond to the highest-resolution shells.reiterating that the PxLPxL/I motif is a prerequisite for the inter-
action and the sequence at the core motif and the flanking re-
gions contribute to the optimal binding, thereby dictating the
preference for ANKRA2 or RFXANK. These results demonstrate
that the PxLPxL motif of CCDC8 is efficient in mediating interac-
tion with ANKRA2.
Structural Analysis of ANKRA2 Bound to the PxLPxL
Motif of CCDC8
To gain structural insights into ANKRA2 interaction with themotif
of CCDC8, we determined the crystal structure of ANKRA2 (res-
idues 142–313, corresponding to the ankyrin-repeat domain;
Figure 1A; Figure S1) in complex with CCDC8 (residues 494–
510). The complex structure was solved at a resolution of 1.8 A˚
(Table 1). Only H498-P510 of CCDC8 displayed visible electron
density in the costructure. As in the ANKRA2-HDAC4 structure
(Xu et al., 2012), the ANKRA2-binding motif (500-PRLPTL-505)
of CCDC8 is characteristic of the PxLPxL/I motif from HDAC4
and megalin, making extensive hydrophobic contacts with an-
kyrin repeats of ANKRA2 (Figure 5; Figure S6). P500 of CCDC8
fits into the hydrophobic pocket formed by F183, W188, A191,
H192, and L221 of ANKRA2 (Figure 5; Figure S6). L502 of
CCDC8 occupies a second pocket composed of E216, S220,
L221, and Y254 of ANKRA2 (Figure 5; Figure S6). P503 of
CCDC8 provides additional hydrophobic contact with Y254
andH257 of ANKRA2 (Figure 5; Figure S6). L505 of CCDC8 binds
to a third hydrophobic pocket consisting of L291, Y282, H257,
and L287 of ANKRA2 (Figure 5; Figure S6). In addition to these
four key residues in the ANKRA2-binding motif, T499 near the
N terminus of the CCDC8 peptide packs against the rings ofStructure 23F183 and W188 of ANKRA2 (Figure 5; Figures S6 and S7). At
the C terminus, P506 of CCDC8 mediates additional hydropho-
bic interactions with H257, Y282, and L287 of ANKRA2 (Figure 5;
Figures S6 and S7). Moreover, the backbone of the CCDC8 pep-
tide forms two hydrogen bonds with Y282 and S280 of ANKRA2
(Figures S6 and S7). These hydrogen bonds and the additional
hydrophobic contacts with the N- and C-terminal ends of the
CCDC8 peptide (Figure 5; Figures S6 and S7) explain the much
stronger ANKRA2-binding affinity for CCDC8 than that for
HDAC4 (0.18 versus 1.6 mM, Figures 3 and 4A).
Wehave recently reported thatS350phosphorylationofHDAC4
decreases the binding (Xu et al., 2012). By contrast, T504 phos-
phorylation of the CCDC8 peptide only weakened the binding
slightly (by 2.5-fold) (Figure 3). There is no detectable binding
between the phosphorylated CCDC8 peptide and 14-3-3g (Fig-
ure 3F), which binds the phosphorylated HDAC4 peptide at a Kd
value of 9 mM (Figure 4A) (Xu et al., 2012). Next, we compared
the two phosphorylated motifs of HDAC4 and CCDC8 centered
at pS350 and pT504, respectively. Sequence comparison indi-
cated that K507 of CCDC8 is at the (i + 3) position, corresponding
to the position of N353 of HDAC4 (Figure 4B). The latter has a
shorter side chain and forms twohydrogenbondswith 14-3-3 res-
idues (Xu et al., 2012). The side chain of K507 of CCDC8 may
cause steric clashwith those residues in 14-3-3g. This conclusion
is further supported by the isothermal titration calorimetry (ITC)
data that 14-3-3g binds to the phosphorylated CCDC8 peptide
very weakly (Figures 3F and 4A).
CCDC8 Serves as a Scaffold for Interaction with OBSL1,
CUL7, and ANKRA2
Having established that the C-terminal PxLPxL motif of CCDC8
mediates the interaction with ANKRA2, we wondered how this
might affect CCDC8 association with OBSL1, a novel protein, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 705
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Figure 5. Detailed Atomic Interactions of the Ankyrin Repeats of ANKRA2 with the CCDC8 Peptide
(A) The ankyrin repeats and theCCDC8 peptide are depicted in pale cyan cartoon and yellow sticks, respectively. Residues of ANKRA2 involved in interactionwith
CCDC8 are shown with sticks. The CCDC8 peptide sequence is the same as listed in Figure 3A.
(B) The ankyrin repeats of ANKRA2 are illustrated in electrostatic surface representation. Key residues of the ANKRA2-binding motif in the CCDC8 peptide are
highlighted and labeled in red. See also Figures S6 and S7.similar to the N-terminal portion of the giant 720-kDa sarcomeric
signaling regulator obscurin (Geisler et al., 2007; Hanson et al.,
2009), and CUL7, an E3 ubiquitin ligase for p53 and several other
proteins (Arai et al., 2003; Dias et al., 2002; Furukawa et al., 2003;
Huber et al., 2005; Litterman et al., 2011; Xu et al., 2008). For this,706 Structure 23, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rightsco-IP was performed. OBSL1 coimmunoprecipitated with
CCDC8 and enhanced the interaction of CCDC8 with ANKRA2
(Figure 6A, lanes 1–4) and bridged the binding of CCDC8 to
CUL7 (lanes 7–8). While an increased amount of CUL7 might
have slightly weakened the ANKRA2 binding to CCDC8 (lanesreserved
5–6), an increase in the ANKRA2 amount had minimal impact on
CUL7 association with CCDC8 (cf. lanes 5 and 9). The point mu-
tation P503A of CCDC8 disrupted its ability to bind ANKRA2 but
exerted no impact on the association with OBSL1 and CUL7
(lanes 10–13), indicating that the C-terminal domain of CCDC8
is important for interaction with ANKRA2 but not OBSL1 and
CUL7. In support for this, a CCDC8 mutant lacking the C-termi-
nal domain coprecipitated with OBSL1 and CUL7 (Figure S5C)
but not with ANKRA2 (Figure 2C). OBSL1N, an N-terminal frag-
ment corresponding to a mutant encoded in a patient with 3M
syndrome (Geisler et al., 2007; Hanson et al., 2009), was suffi-
cient for CCDC8 binding (Figure 6A, lane 14). These results indi-
cate that OBSL1 serves as a scaffold to bridge interaction of
CUL7 with CCDC8, which in turn associates with ANKRA2 (Fig-
ure 6B). The complex formation among CCDC8, OBSL1, and
CUL7 is consistent with a recent report (Yan et al., 2014).
CUL7 is a large protein with multiple domains (Arai et al., 2003;
Dias et al., 2002; Furukawa et al., 2003; Xu et al., 2008), so we
mapped the domain that mediates interaction with OBSL1 and
CCDC8. For this, co-IP was performed, which revealed that
the cullin-containing C-terminal portion of CUL7 is necessary
and sufficient for associationwithOBSL1 andCCDC8 (Figure 6C,
lanes 5–6 and 12–13). As the cullin domain is responsible for
interaction with the RING finger protein ROC1 and for the E3
ubiquitin ligase activity (Arai et al., 2003; Dias et al., 2002; Furu-
kawa et al., 2003; Xu et al., 2008), an interesting possibility
is whether the OBSL1/CCDC8 subcomplex competes with
ROC1 in binding to the cullin domain. As shown in Figure 6C,
ROC1 bound to CUL7 in the presence of expressed OBSL1
and CCDC8 (lanes 1–4 and 8–11), indicating that OBSL1 and
CCDC8do not interfere with ROC1 recruitment to CUL7. Alterna-
tively, two CUL7 populations may form different complexes with
OBSL1/CCDC8 and ROC1. Moreover, the C-terminal fragment
of CUL7 interacted with ROC1 (lanes 5–7 and 12–14), indicating
that the cullin domain possesses sites for simultaneous interac-
tion with the OBSL1/CCDC8 and ROC1/FBXW8 subcomplexes.
Interestingly, autoubiquination of the cullin domain appeared to
be inhibited byOBSL1 andCCDC8 (Figure 6C, lanes 5–6). There-
fore, using its N- and C-terminal domains, CCDC8 serves as a
scaffold for interaction with OBSL1 and ANKRA2, respectively,
whereas OBSL1 in turn targets CCDC8 to the cullin domain of
CUL7 (Figure 6D).
ANKRA2 Inhibits Interaction of CUL7 with HDAC4
As an E3 ubiquitin ligase (Arai et al., 2003; Dias et al., 2002;
Furukawa et al., 2003), CUL7 stimulates ubiquitination of p53
(Andrews et al., 2006), insulin receptor substrate (Litterman
et al., 2011; Xu et al., 2008), and TBC1D3 (Kong et al., 2012).
We thus asked whether ANKRA2 regulates the ligase activity
of CUL7 toward these substrates. Cell-based ubiquitination
assays failed to detect any effects of ANKRA2 on p53 and
TBC1D3 (data not shown), so we wondered whether CUL7 tar-
gets unidentified substrates. Because ANKRA2 interacts with
the class IIa histone deacetylases (McKinsey et al., 2006;
Wang et al., 2005), we investigated whether CUL7 binds to these
deacetylases. As shown in Figure 7 (lanes 4, 10, 15, and 21), both
HDAC4 and HDAC5 coimmunoprecipitated with CUL7. Interest-
ingly, coexpression of ANKRA2 blocked interaction of CUL7 with
both deacetylases (lanes 5, 11, 16, and 22). Strikingly, both wereStructure 23more stable when ANKRA2 was coexpressed (cf. lanes 15 and
21 with lanes 16 and 22, respectively). We also analyzed the mu-
tants I354A and P349A, which contain point mutations at the
ANKRA2-binding PxLPxL motif of HDAC4 and disrupt ANKRA2
binding in vitro (data not shown). In the cells, both mutants still
interacted with ANKRA2 as efficiently as wild-type HDAC4 (Fig-
ure 7, lanes 1–3 and 12–14), indicating that in addition to the
PxLPxL motif, HDAC4 contains other sites for ANKRA2 binding,
as reported earlier (Wang et al., 2005). Bothmutants were slightly
less stable than wild-type HDAC4 but were able to bind CUL7
(lanes 4–6 and 15–17). Interestingly, ANKRA2 disrupted the inter-
action (lanes 7–9 and 18–20). These results indicate that
ANKRA2 binds HDAC4 to block its access by CUL7.
DISCUSSION
This study uncovers a link of the ankyrin-repeat protein ANKRA2
to CCDC8, OBSL1, and CUL7 (Figure 8), thereby shedding light
on the molecular mechanisms underlying the pathogenesis of
3M syndrome, a unique form of primordial dwarfism (Clayton
et al., 2012; Klingseisen and Jackson, 2011). The proteomic sur-
vey identified CCDC8 as a major partner of ANKRA2 (Figure 1B).
The PxLPxL motif of CCDC8 is necessary and sufficient for the
association (Figures 2 and 3). At the sequence level, this motif
is more similar to those of HDAC4, megalin, and RFX7 than to
that of RFX5 (Figure 4B). Indeed, the motif mediates interaction
with ANKRA2 but not with RFXANK (Figure 3). The CCDC8 affin-
ity for ANKRA2 is even higher than that of HDAC4, megalin, or
RFX7 (Figure 4A), explaining why CCDC8 was recovered as
the top partner of ANKRA2 (Figure 1B). The atomic interactions
are highly similar to those in structures of the ANKRA2 com-
plexes with the HDAC4, megalin, and RFX7 peptides (Figure 5;
Figures S6 and S7), but CCDC8 also possesses extra contacts
with ANKRA2 (Figure S7), making the binding affinity higher
than that for HDAC4, megalin, or RFX7 (Figure 4A). Therefore,
in addition to the core motif PxLPxL/I, exact sequences within
themotif and surrounding regions are important for optimal inter-
action with ANKRA2 and RFXANK.
While the PxLPxL motif of CCDC8 is located at its C-terminal
domain (Figure 4), OBSL1 targets the N-terminal domain to
promote the interaction with the CUL7 ligase (Figure 8). CUL7
stimulates ubiquitination of p53, insulin receptor substrate 1,
and the hominoid-specific TBC1D3 oncoprotein (Andrews
et al., 2006; Kong et al., 2012; Xu et al., 2008). Related to the
interaction of CUL7 with p53, CCDC8 was recently reported to
bind p53 (Dai et al., 2011). Our results indicate that ANKRA2
does not affect p53 ubiquitination (data not shown). Instead,
we found that ANKRA2 blocks CUL7 interaction with HDAC4/5
and perhaps also the other two class IIa deacetylases (Figure 7)
(Yang and Seto, 2008).
The CCDC8, CUL7, andOBSL1 genes are mutated in patients
with 3M syndrome (Al-Dosari et al., 2012; Hanson et al., 2011).
The unexpected identification of CCDC8 as a major partner of
ANKRA2 (Figure 1B) suggests an important role of ANKRA2 in
3M syndrome. Whether the gene is mutated in the patients
lacking mutations in the CUL7, OBSL1, and CCDC8 genes is
an interesting possibility worth consideration. ANKRA2 may
also modify the outcome in patients who carry mutations in the
CUL7, OBSL1, and CCDC8 genes. In addition to short stature,, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 707
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Figure 6. OBSL1 Promotes the Interaction of CCDC8 with CUL7 and ANKRA2
(A) Expression vectors for the indicated mCherry (mCh) fusion proteins were transfected into HEK293 cells along with the expression plasmid for Flag-tagged
CCDC8 or its point mutant P503A. Soluble extracts were prepared for affinity purification and immunoblotting.
(B) Cartoon illustrating that OBSL1 mediates interaction of CUL7 with CUL7 to the N-terminal domain (N) whereas ANKRA2 binds to the PxLPxL motif located at
the C-terminal domain (P).
(legend continued on next page)
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Figure 7. ANKRA2 Inhibits Interaction of
CUL7 with HDAC4 and HDAC5
Expression vectors for mCh tagged CUL7 and
ANKRA2 were separately or simultaneously
transfected into HEK293 cells along with the
expression plasmid for Flag-tagged HDAC4, two
point mutants, and HDAC5 as indicated. Soluble
extracts were prepared for affinity purification and
immunoblotting. The point mutants P349A and
I354A contain mutations replacing the key resi-
dues P349 and I354, respectively, within the
ANKRA2-binding PxLPxL motif of HDAC4 with
alanine and display minimal ANKRA2 binding
in vitro (data not shown), but both mutants still
interact with ANKRA2 efficiently in HEK293 cells.
Thus, in the cells, HDAC4 contains multiple
ANKRA2-binding sites as reported earlier (Wang
et al., 2005).patients with 3M syndrome display unusual facial features and
skeletal abnormalities (Clayton et al., 2012; Hanson et al.,
2011, 2012; Litterman et al., 2011). ANKRA2 impairs CUL7 bind-
ing to HDAC4 (Figure 7). Haploinsufficiency of the HDAC4 gene
leads to craniofacial and skeletal abnormalities (Williams et al.,
2010), and the mouse ortholog is crucial for skeletal develop-
ment (Vega et al., 2004). 3M syndrome is underdiagnosed (Al-
Dosari et al., 2012) and displays similarity to other primordial
growth disorders, such as Yakut short-stature syndrome (Maksi-
mova et al., 2007) and Silver-Russell syndrome (Akawi et al.,
2011). Thus, the unexpected molecular link uncovered herein
provides an important lead about the mechanisms underlying
3M syndrome and other primordial dwarfism.
While RFXANK forms a trimeric transcription factor complex
with RFX5 and RFXAP to recruit the coactivator CIITA for regu-
lating gene expression programs that are affected in BLS pa-
tients (Reith andMach, 2001; Ting and Trowsdale, 2002), the bio-
logical function of ANKRA2 remains unclear. Its high sequence
similarity to RFXANK (Figure 1A; Figure S1) suggests that
ANKRA2 plays a similar role in vivo. However, unlike the
RFXANK, RFX5, RFXAP, and CIITA genes, the ANKRA2 gene
has never been recovered as one mutated in BLS patients (Reith
andMach, 2001; Ting and Trowsdale, 2002). Related to this, only
ANKRA2 was identified as the partner of megalin, HDAC4, and
HDAC5 in yeast two-hybrid screening of different libraries
(McKinsey et al., 2006; Rader et al., 2000; Wang et al., 2005).
Thus, there are functional differences between ANKRA2 and
RFXANK, even although they behave similarly in cell-based as-
says (Krawczyk et al., 2005; Long and Boss, 2005; McKinsey
et al., 2006; Wang et al., 2005). In support of this, recent quanti-
tative binding and crystal structural analyses showed that one
key residue (H257 of ANKRA2 and R199 of RFXANK, Figure S1)(C) Expression vectors for HA-ROC1 and the indicatedmCh fusion proteins were transfected into HEK293 cells
CUL7 or its truncation mutant containing the C-terminal cullin domain. Soluble extracts were prepared for
denote nonspecific bands.
(D) Cartoon illustrating interaction of the C-terminal cullin domain CUL7 with the OBSL1/CCDC8 and ROC1/
Structure 23, 700–712, April 7, 2015plays a dominant role in dictating speci-
ficity in partner selection (Xu et al.,
2012). The proteomic survey presentedherein reiterates the functional similarity and difference between
ANKRA2 and RFXANK (Figure 1B; Tables S1 and S2). As ex-
pected from the published studies (Krawczyk et al., 2005; Long
and Boss, 2005), RFXANK and ANKRA2 coprecipitated with
RFX5 and RFXAP. While RFX5 was recovered as the top partner
of RFXANK, CCDC8 was identified as the major partner of
ANKRA2 (Figure 1B; Table S1). In contrast, CCDC8 did not cop-
urify with RFXANK, supporting that RFXANK and ANKRA2 have
different targets and functions in vivo (Figure 1C). Of relevance,
histones H3.1 and H3.3 are almost identical (sequence identity
>95%), but their targets and functions are different in vivo (Gold-
berg et al., 2010).
RFX7 is ranked the second in purifications for both baits (Fig-
ure 1B; Tables S1 and S2). This is a novel protein linked to breast
cancer and neural tube development (Aftab et al., 2008; Bae
et al., 2014; Manojlovic et al., 2014; Yau et al., 2010), RFX7 dis-
plays significant similarity in its putative DNA binding domain
with the RFX domain of RFX5 (Figure S3). Within this domain is
a PxLPxL motif. However, the motif is more similar to those of
HDAC4 and megalin than to that of RFX5 (Figure 4; Figure S3).
In particular, P175 of RFX5, a key residue making it preferable
for RFXANK binding (Xu et al., 2012), is not conserved in RFX7.
Thus, RFX7 prefers ANKRA2 over RFXANK (Figure 4; Figure S7).
The Drosophila homolog is more similar to RFX7 than RFX5 (Fig-
ure S3), and there are no apparent RFXAP homologs in the fly,
suggesting that the RFX7-ANKRA2 link is conserved from flies
to humans.
Among the proteins copurified with RFXANK and ANKRA2,
CCDC8, RFX7, and HDAC5 are the only three containing
conserved PxLPxL/I motifs (Figure 1B; Tables S1 and S2), so
the interesting question is how the other partners such as the
ubiquitin E3 ligase HUWE1 and the uncharacterized proteinalongwith the expression plasmid for Flag-tagged
affinity purification and immunoblotting. Asterisks
FBXW8 subcomplexes. See also Figure S5C.
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Figure 8. Model Explaining How ANKRA2 Interacts with CCDC8 and
May Regulate Functions of HDAC4/5 and RFX7
Acting as a multidomain scaffold, CCDC8 uses the N-terminal part (composed
of the uncharacterized CP andWWdomains) for binding to OBSL1, with in turn
recruits the CUL7 ubiquitin ligase complex for regulating ubiquitination of its
substrates. The C-terminal region of CCDC8 is required for interaction with
ANKRA2 and also for an unidentified factor (not illustrated). The suggestion for
this unidentified factor is based on the observation that the entire C-terminal
region is highly conserved from mouse to humans (Figure S4) and the PxLPxL
motif is embedded within this region. ANKRA2 binds to the PxLPxL motif of
CCDC8 and inhibits interaction of CUL7 with (and perhaps also ubiquitination
of) HDAC4/5 and RFX7. Structural domains of CCDC8 are illustrated and
labeled as in Figure 2A. Three 3M syndrome-causing mutations are located at
the coding sequence for the N-terminal portion of CCDC8 and are expected to
result in expression of aberrant proteins to disrupt the network formed with
CUL7, OBSL1, and ANKRA2. See also Figure S7.C20orf117 (Figure 1B) may interact with ANKRA2 and RFXANK.
One possibility is that the interaction is facilitated or mediated
by others. For example, RFX5 facilitates RFXANK association
with RFXAP, and CCDC8 bridges interaction of CUL7, OBSL1,
and FBXW8 with ANKRA2 (Figure 1C). Another possibility is
that some of the associated proteins directly interact with
ANKRA2 and RFXANK in a manner independent of PxLPxL/I
motifs.
In summary, proteomic analysis of proteins interacting with
the two paralogous ankyrin-repeat proteins ANKRA2 and
RFXANK has uncovered two groups of proteins with genes
that are mutated in 3M syndrome and BLS. ANKRA2 recog-
nizes a conserved PxLPxL motif on the eutherian-specific
protein CCDC8, which in turn interacts with the cytoskeletal
protein OBSL1 and the ubiquitin ligase CUL7 (Figure 8). Func-
tionally, ANKRA2 inhibits CUL7 interaction with HDAC4/5 (Fig-
ure 8). How CUL7-mediated ubiquitination is involved in the
regulation is an interesting question awaiting further investiga-
tion (Figure 8).EXPERIMENTAL PROCEDURES
Protein Expression in Mammalian Cells and Affinity Protein
Purification
We expressed ANKRA2 and RFXANK asGFP-tagged fusion proteins in human
embryonic kidney (HEK) 293 cells. The GFP fusion tag was not only to detect
and visualize the protein expression but also to take advantage of the high
specificity and low background of GFP-Trap affinity beads developed from a
unique camel single-chain antibody (Allele Biotechnology and ChromoTek)
(Rothbauer et al., 2008). The GFP fusion proteins were affinity purified on the710 Structure 23, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rightsbeads and specifically associated proteins were analyzed by mass spectrom-
etry. This procedure is commonly referred to as IP-MS, in which the relative
abundance of each interacting protein is reflected in their total spectrum
counts of the resulting tryptic peptides (Figure 1B; Table S1).
Bacterial Protein Expression, Purification, and Crystallization
Preparation of human ANKRA2 ankyrin repeats was performed as described
(Xu et al., 2012). For crystallization, the purified ANKRA2 protein was mixed
with the CCDC8 peptide corresponding to residues 494–510 at a ratio of
1:2, and crystals of the complex were obtained with the hanging-drop vapor
diffusion method at 18C in a crystallization buffer containing 0.1 M HEPES
(pH 7.5), 0.2 M NaCl, and 25% PEG 3350. The crystals were frozen in liquid
nitrogen without cryoprotectants.
Collection and Analysis of Crystal Structural Data
Three hundred and sixty half-degree oscillation images, collected on a copper-
rotating anode equippedwith an image plate detector (Rigaku FR-E and Raxis-
IV-HTC, respectively), were reduced using the XDS program (Kabsch, 2010).
Reflections were scaled using POINTLESS/SCALA (Evans, 2006) and con-
verted to structure factor amplitudes with TRUNCATE (French and Wilson,
1978). The structure was solved by molecular replacement with the published
coordinates from the PDB entry 3SO8 and the programPHASER (McCoy et al.,
2007). The model was rebuilt, refined, and validated in several iterations,
respectively, using COOT (Emsley et al., 2010), REFMAC (Murshudov et al.,
2011), and the MOLPROBITY server (Chen et al., 2010).
ITC
ITC measurements were recorded at 25C using a VP-ITC microcalorimeter
(MicroCal) as described (Xu et al., 2012). To determine the Kd value of
CCDC8 binding to ANKRA2, 10 ml of the peptide solution (residues 494–
510 of CCDC8, Figure 4B; 1.0 mM) was injected into a sample cell containing
40 or 80 mM of the ANKRA2 ankyrin-repeat fragment (residues 142–313) in
20 mM Tris-HCl (pH 7.5) and 150 mM NaCl. For binding to RFXANK, 10 ml
of the CCDC8 peptide solution (0.5 mM) was injected into a sample cell con-
taining 35 mM of the RFXANK ankyrin-repeat fragment (residues 90–260). For
binding to 14-3-3, 10 ml of the pT504 CCDC8 peptide solution (Figure 4B,
1.0 mM) was injected into a sample cell containing 50 mM of 14-3-3g. For
RFX7 binding to ANKRA2, 10 ml of the RFX7 peptide solution (Figure 4B,
1.0 mM) was injected into a sample cell containing 50 mM of the ANKRA2
fragment. For binding to ANKRA2, 10 ml of the RFX7 peptide solution
(2.0 mM) was injected into a sample cell containing 100 mM of the ANKRA2
fragment. The concentrations of protein and peptide were estimated with
absorbance spectroscopy using the extinction coefficients. A total of 25 in-
jections were performed with an interval of 180 s and a reference power of
15 mcal/s. Binding isotherms were plotted using a one-site binding model
analyzed by Origin Software (MicroCal).
Co-IP
HEK293 cells were seeded in 6-cm dishes at 0.5 3 106 cells per dish and
transiently transfected with the expression plasmids for Flag-tagged
CCDC8 or its mutants along expressing plasmids for GFP-ANKRA2, GFP-
tagged ANKRA2 point mutants, and GFP-RFXANK as indicated. Two days
post transfection, the cells were washed twice with PBS and lysed in situ
with 0.1 ml of cold buffer K for preparation of soluble extracts as described
(Ullah et al., 2008). Co-IP was performed with anti-Flag M2 agarose (Sigma)
and specifically bound proteins were eluted with FLAG peptide (Sigma) for
immunoblotting with anti-FLAG (Sigma, clone M2), anti-GFP (Santa Cruz
Biotech, B-2, sc-9996), and anti-mCherry (BioVision, 5993-100) antibodies
as specified.
Additional experimental procedures are included in the Supplemental
Information.
ACCESSION NUMBERS
Atomic coordinates for the ANKRA2 complex structures with the CCDC8,
RFX7, HDAC4, and megalin peptides have been deposited in PDB under the
entry codes 4LG6, 4QQI, 3V31, and 3V2X, respectively.reserved
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.str.2015.02.001.
AUTHOR CONTRIBUTIONS
J.N. initiated the project and verified the interaction of ANKRA2 with the
PxLPxL motif of CCDC8; C.X. and W.T. carried out X-ray crystallography
and structural determination; C.X. performed the ITC experiments and
analyzed the data; J.J. and V.N. carried out mass spectrometry; J.N. and
J.A.A. determined the interaction of CCDC8 with OBSL1 and CUL7; J.A.A.
analyzed the interaction of HDAC4/5 with CUL7 and ANKRA2; L.Y. and R.W.
provided reagents; X.J.Y., J.M., and T.P. supervised the project; X.J.Y, J.M.,
C.X., and J.J. wrote the manuscript.
ACKNOWLEDGMENTS
This research was supported by operating grants from the Canadian Institutes
for Health Research (CIHR, to X.J.Y. and T.P.), as well as by the Structural Ge-
nomics Consortium, a registered charity that received funds from the CIHR,
the Canadian Foundation for Innovation, Genome Canada through the Ontario
Genomics Institute, GlaxoSmithKline, Karolinska Institute, the Knut and Alice
Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for
Research and Innovation, Merck & Co., Inc., the Novartis Research Founda-
tion, the Swedish Agency for Innovation Systems, the Swedish Foundation
for Strategic Research and the Wellcome Trust.
Received: December 3, 2014
Revised: February 2, 2015
Accepted: February 3, 2015
Published: March 5, 2015
REFERENCES
Aftab, S., Semenec, L., Chu, J.S., and Chen, N. (2008). Identification and char-
acterization of novel human tissue-specific RFX transcription factors. BMC
Evol. Biol. 8, 226.
Akawi, N.A., Ali, B.R., Hamamy, H., Al-Hadidy, A., and Al-Gazali, L. (2011). Is
autosomal recessive Silver-Russel syndrome a separate entity or is it part of
the 3-M syndrome spectrum? Am. J. Med. Genet. A 155A, 1236–1245.
Al-Dosari, M.S., Al-Shammari, M., Shaheen, R., Faqeih, E., Alghofely, M.A.,
Boukai, A., and Alkuraya, F.S. (2012). 3M syndrome: an easily recognizable
yet underdiagnosed cause of proportionate short stature. J. Pediatr. 161,
139.e1–145.e1.
Andrews, P., He, Y.J., and Xiong, Y. (2006). Cytoplasmic localized ubiquitin
ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 func-
tion. Oncogene 25, 4534–4548.
Arai, T., Kasper, J.S., Skaar, J.R., Ali, S.H., Takahashi, C., and DeCaprio, J.A.
(2003). Targeted disruption of p185/Cul7 gene results in abnormal vascular
morphogenesis. Proc. Natl. Acad. Sci. USA 100, 9855–9860.
Bae, B., Tietjen, I., Atabay, K.D., Evrony, G.D., Johnson,M.B., Asare, E.,Wang,
P.P., Murayama, A.Y., Im, K., Lisgo, S.N., et al. (2014). Evolutionarily dynamic
alternative splicing of GPR56 regulates regional cerebral cortical patterning.
Science 343, 746–768.
Chen, H.L., and D’Mello, S.R. (2010). Induction of neuronal cell death by para-
neoplastic Ma1 antigen. J. Neurosci. Res. 88, 3508–3519.
Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M.,
Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010).
MolProbity: all-atom structure validation for macromolecular crystallography.
Acta Crystallogr. D Biol. Crystallogr. 66, 12–21.
Christensen, E.I., and Birn, H. (2002). Megalin and cubilin: multifunctional
endocytic receptors. Nat. Rev. Mol. Cell Biol. 3, 256–266.
Clayton, P.E., Hanson, D., Magee, L., Murray, P.G., Saunders, E., Abu-Amero,
S.N., Moore, G.E., and Black, G.C. (2012). Exploring the spectrum of 3-M syn-Structure 23drome, a primordial short stature disorder of disrupted ubiquitination. Clin.
Endocrinol. (Oxf) 77, 335–342.
Dai, C., Tang, Y., Jung, S.Y., Qin, J., Aaronson, S.A., and Gu, W. (2011).
Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90.
Proc. Natl. Acad. Sci. USA 108, 18937–18942.
Dias, D.C., Dolios, G., Wang, R., and Pan, Z.Q. (2002). CUL7: a DOC domain-
containing cullin selectively binds Skp1.Fbx29 to form an SCF-like complex.
Proc. Natl. Acad. Sci. USA 99, 16601–16606.
Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.
Evans, P. (2006). Scaling and assessment of data quality. Acta Crystallogr. D
Biol. Crystallogr. 62, 72–82.
French, S., and Wilson, K. (1978). Treatment of negative intensity observa-
tions. Acta Crystallogr. A 34, 517–525.
Furukawa,M., He, Y.J., Borchers, C., and Xiong, Y. (2003). Targeting of protein
ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. Nat. Cell Biol. 5, 1001–
1007.
Geisler, S.B., Robinson, D., Hauringa, M., Raeker, M.O., Borisov, A.B.,
Westfall, M.V., and Russell, M.W. (2007). Obscurin-like 1, OBSL1, is a novel
cytoskeletal protein related to obscurin. Genomics 89, 521–531.
Goldberg, A.D., Banaszynski, L.A., Noh, K.M., Lewis, P.W., Elsaesser, S.J.,
Stadler, S., Dewell, S., Law, M., Guo, X., Li, X., et al. (2010). Distinct factors
control histone variant H3.3 localization at specific genomic regions. Cell
140, 678–691.
Hanson, D., Murray, P.G., Sud, A., Temtamy, S.A., Aglan, M., Superti-Furga,
A., Holder, S.E., Urquhart, J., Hilton, E., Manson, F.D., et al. (2009). The primor-
dial growth disorder 3-M syndrome connects ubiquitination to the cytoskeletal
adaptor OBSL1. Am. J. Hum. Genet. 84, 801–806.
Hanson, D., Murray, P.G., O’Sullivan, J., Urquhart, J., Daly, S., Bhaskar, S.S.,
Biesecker, L.G., Skae, M., Smith, C., Cole, T., et al. (2011). Exome sequencing
identifies CCDC8 mutations in 3-M syndrome, suggesting that CCDC8 con-
tributes in a pathway with CUL7 and OBSL1 to control human growth. Am.
J. Hum. Genet. 89, 148–153.
Hanson, D., Murray, P.G., Coulson, T., Sud, A., Omokanye, A., Stratta, E.,
Sakhinia, F., Bonshek, C., Wilson, L.C., Wakeling, E., et al. (2012). Mutations
in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered growth fac-
tor signalling. J. Mol. Endocrinol. 49, 267–275.
Huber, C., Dias-Santagata, D., Glaser, A., O’Sullivan, J., Brauner, R., Wu, K.,
Xu, X., Pearce, K., Wang, R., Uzielli, M.L., et al. (2005). Identification of muta-
tions in CUL7 in 3-M syndrome. Nat. Genet. 37, 1119–1124.
Kabsch, W. (2010). Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132.
Klingseisen, A., and Jackson, A.P. (2011). Mechanisms and pathways of
growth failure in primordial dwarfism. Genes Dev. 25, 2011–2024.
Kong, C., Samovski, D., Srikanth, P., Wainszelbaum, M.J., Charron, A.J., Liu,
J., Lange, J.J., Chen, P.I., Pan, Z.Q., Su, X., et al. (2012). Ubiquitination and
degradation of the hominoid-specific oncoprotein TBC1D3 is mediated by
CUL7 E3 ligase. PLoS One 7, e46485.
Krawczyk, M., Masternak, K., Zufferey, M., Barras, E., and Reith, W. (2005).
New functions of the major histocompatibility complex class II-specific tran-
scription factor RFXANK revealed by a high-resolution mutagenesis study.
Mol. Cell. Biol. 25, 8607–8618.
Lin, J.H., Makris, A., McMahon, C., Bear, S.E., Patriotis, C., Prasad, V.R.,
Brent, R., Golemis, E.A., and Tsichlis, P.N. (1999). The ankyrin repeat-contain-
ing adaptor protein Tvl-1 is a novel substrate and regulator of Raf-1. J. Biol.
Chem. 274, 14706–14715.
Litterman, N., Ikeuchi, Y., Gallardo, G., O’Connell, B.C., Sowa, M.E., Gygi,
S.P., Harper, J.W., and Bonni, A. (2011). An OBSL1-Cul7Fbxw8 ubiquitin
ligase signaling mechanism regulates Golgi morphology and dendrite
patterning. PLoS Biol. 9, e1001060.
Long, A.B., and Boss, J.M. (2005). Evolutionary conservation and character-
ization of the bare lymphocyte syndrome transcription factor RFX-B and its pa-
ralogue ANKRA2. Immunogenetics 56, 788–797.
Maksimova, N., Hara, K., Miyashia, A., Nikolaeva, I., Shiga, A., Nogovicina, A.,
Sukhomyasova, A., Argunov, V., Shvedova, A., Ikeuchi, T., et al. (2007)., 700–712, April 7, 2015 ª2015 Elsevier Ltd All rights reserved 711
Clinical, molecular and histopathological features of short stature syndrome
with novel CUL7 mutation in Yakuts: new population isolate in Asia. J. Med.
Genet. 44, 772–778.
Manojlovic, Z., Earwood, R., Kato, A., Stefanovic, B., and Kato, Y. (2014). RFX7
is required for the formation of cilia in the neural tube. Mech. Dev. 132, 28–37.
Masternak, K., Barras, E., Zufferey, M., Conrad, B., Corthals, G., Aebersold,
R., Sanchez, J.C., Hochstrasser, D.F., Mach, B., and Reith, W. (1998). A
gene encoding a novel RFX-associated transactivator is mutated in the major-
ity of MHC class II deficiency patients. Nat. Genet. 20, 273–277.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C.,
and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Crystallogr.
40, 658–674.
McKinsey, T.A., Kuwahara, K., Bezprozvannaya, S., and Olson, E.N. (2006).
Class II histone deacetylases confer signal responsiveness to the ankyrin-
repeat proteins ANKRA2 and RFXANK. Mol. Biol. Cell 17, 438–447.
Miller, J.D., McKusick, V.A., Malvaux, P., Temtamy, S., and Salinas, C. (1975).
The 3-M syndrome: a heritable low birthweight dwarfism. Birth Defects Orig.
Artic. Ser. 11, 39–47.
Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A.,
Nicholls, R.A., Winn, M.D., Long, F., and Vagin, A.A. (2011). REFMAC5 for
the refinement of macromolecular crystal structures. Acta Crystallogr. D
Biol. Crystallogr. 67, 355–367.
Nagarajan, U.M., Louis-Plence, P., DeSandro, A., Nilsen, R., Bushey, A., and
Boss, J.M. (1999). RFX-B is the gene responsible for the most common cause
of the bare lymphocyte syndrome, an MHC class II immunodeficiency.
Immunity 10, 153–162.
Rader, K., Orlando, R.A., Lou, X., and Farquhar, M.G. (2000). Characterization
of ANKRA, a novel ankyrin repeat protein that interacts with the cytoplasmic
domain of megalin. J. Am. Soc. Nephrol. 11, 2167–2178.
Reith, W., and Mach, B. (2001). The bare lymphocyte syndrome and the regu-
lation of MHC expression. Annu. Rev. Immunol. 19, 331–373.
Rothbauer, U., Zolghadr, K., Muyldermans, S., Schepers, A., Cardoso, M.C.,
and Leonhardt, H. (2008). A versatile nanotrap for biochemical and functional
studies with fluorescent fusion proteins. Mol. Cell. Proteomics 7, 282–289.
Schuller, M., Jenne, D., and Voltz, R. (2005). The human PNMA family: novel
neuronal proteins implicated in paraneoplastic neurological disease.
J. Neuroimmunol. 169, 172–176.
Ting, J.P., and Trowsdale, J. (2002). Genetic control of MHC class II expres-
sion. Cell 109, S21–S33.712 Structure 23, 700–712, April 7, 2015 ª2015 Elsevier Ltd All rightsUllah, M., Pelletier, N., Xiao, L., Zhao, S.P., Wang, K., Degerny, C., Tahmasebi,
S., Cayrou, C., Doyon, Y., Goh, S.L., et al. (2008). Molecular architecture of
quartet MOZ/MORF histone acetyltransferase complexes. Mol. Cell. Biol.
28, 6828–6843.
Vega, R.B., Matsuda, K., Oh, J., Barbosa, A.C., Yang, X., Meadows, E.,
McAnally, J., Pomajzl, C., Shelton, J.M., Richardson, J.A., et al. (2004).
Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogene-
sis. Cell 119, 555–566.
Wang, A.H., Gregoire, S., Zika, E., Xiao, L., Li, C.S., Li, H., Wright, K.L., Ting,
J.P., and Yang, X.J. (2005). Identification of the ankyrin repeat proteins
ANKRA and RFXANK as novel partners of class IIa histone deacetylases.
J. Biol. Chem. 280, 29117–29127.
Wang, H., Chen, Y., Lin, P., Li, L., Zhou, G., Liu, G., Logsdon, C., Jin, J.,
Abbruzzese, J.L., and Tan, T.H. (2014). The CUL7/F-box and WD repeat
domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of
hematopoietic progenitor kinase 1. J. Biol. Chem. 289, 4009–4017.
Williams, S.R., Aldred, M.A., Der Kaloustian, V.M., Halal, F., Gowans, G.,
McLeod, D.R., Zondag, S., Toriello, H.V., Magenis, R.E., and Elsea, S.H.
(2010). Haploinsufficiency of HDAC4 causes brachydactyly mental retardation
syndrome, with brachydactyly type E, developmental delays, and behavioral
problems. Am. J. Hum. Genet. 87, 219–228.
Xu, X., Sarikas, A., Dias-Santagata, D.C., Dolios, G., Lafontant, P.J., Tsai, S.C.,
Zhu, W., Nakajima, H., Nakajima, H.O., Field, L.J., et al. (2008). The CUL7 E3
ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent
degradation. Mol. Cell 30, 403–414.
Xu, C., Jin, J., Bian, C., Lam, R., Tian, R., Weist, R., You, L., Nie, J., Bochkarev,
A., Tempel,W., et al. (2012). Sequence-specific recognition of a PxLPxI/Lmotif
by an ankyrin repeat tumbler lock. Sci. Signal. 5, ra39.
Yan, J., Yan, F., Li, Z., Sinnott, B., Cappell, K.M., Yu, Y., Mo, J., Duncan, J.A.,
Chen, X., Cormier-Daire, V., et al. (2014). The 3M complex maintains microtu-
bule and genome integrity. Mol. Cell 54, 791–804.
Yang, X.J., and Seto, E. (2008). The Rpd3/Hda1 family of lysine deacetylases:
from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9, 206–218.
Yau, C., Esserman, L., Moore, D.H., Waldman, F., Sninsky, J., and Benz,
C.C. (2010). A multigene predictor of metastatic outcome in early stage hor-
mone receptor-negative and triple-negative breast cancer. Breast Cancer
Res. 12, R85.reserved
